FDA
-
-
-
-
-
-
-
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
-
-
-
-
-
-
-
Tiziana Life Sciences (TLSA) Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association
-
-
-
-
-
-
-
Tiziana Life Sciences (TLSA) Appoints Ivor Elrifi as CEO
-
-
-
-
-
-
-
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
-
-
-
-
-
-
-
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
-
-
-
-
-
-
-
Tiziana (TLSA) Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS
-
-
-
-
-
-
-
Tiziana Life Sciences (TLSA) to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

